Aptose Biosciences News

Canadian Investment Banking Group: Maintaining the Aptose Biosciences (APTO.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $6.00.

Zhitong FinanceMay 16 23:50

Aptose Biosciences Analyst Ratings

BenzingaMay 16 23:45

Buy Rating for Aptose Biosciences on Tuspetinib's Promising AML Study and Synergistic Potential

TipRanksMay 16 18:45

Aptose Biosciences Analyst Ratings

BenzingaApr 3 23:56

Piper Sandler Maintains Overweight on Aptose Biosciences, Maintains $5 Price Target

BenzingaApr 3 23:58

Aptose Biosciences' Strategic Shift to Front-Line AML Therapy Garners Buy Rating

TipRanksMar 28 05:05

Aptose Biosciences Analyst Ratings

BenzingaMar 27 18:21

Aptose Biosciences Analyst Ratings

BenzingaFeb 2 04:08

Piper Sandler Sticks to Its Buy Rating for Aptose Biosciences (APTO)

TipRanksFeb 1 21:09

RBC Capital Maintains Outperform on Aptose Biosciences, Lowers Price Target to $18

BenzingaNov 11, 2023 02:54

Aptose Biosciences Analyst Ratings

BenzingaNov 11, 2023 02:53

Buy Rating for Aptose Biosciences: Tuspetinib's Promising Future and Differentiation in FLT3 Inhibition

TipRanksNov 11, 2023 01:07

Aptose Biosciences (APTO) Gets a Buy From Piper Sandler

TipRanksNov 10, 2023 23:17

RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk

MT NewswiresNov 10, 2023 20:41

Promising Financial Performance and Clinical Developments Bolster Aptose Biosciences' Buy Rating: An Analysis by Joseph Pantginis

TipRanksNov 10, 2023 19:56

Oppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)

TipRanksOct 31, 2023 20:25

Promising Trial Data and Expansion Plans Boost Confidence in Aptose Biosciences: An Analysis of John Newman's Buy Rating

TipRanksOct 31, 2023 19:17

Joseph Pantginis Gives Buy Rating to Aptose Biosciences: Promising Clinical Trials and Strong Safety Profile Drive Recommendation

TipRanksOct 30, 2023 23:05

Promising Prospects of Tuspetinib Drive Buy Rating for Aptose Biosciences: An Analyst's Perspective

TipRanksOct 20, 2023 18:22

JonesTrading Analyst Gives a Buy Rating to Aptose Biosciences: Highlights Tuspetinib's Prospects and Anticipates Key Updates at ESH and ASH Conferences

TipRanksSep 29, 2023 02:45